Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.72 |
| ▸ | BRD4 | O60885 | 4/20 | 0.63 |
| ▸ | BRD2 | P25440 | 4/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 12/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725065 | 0.91 | CYP3A4 (0.77) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2726348 | 0.89 | CYP3A4 (0.73) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2725470 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2724177 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2726751 | 0.85 | CYP3A4 (0.81) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL31424930 | 0.84 | CYP3A4 (1.00) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| Trifluoroacetic Acid SCHEMBL15208747 | 0.84 | CYP3A4 (0.65) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2725841 | 0.83 | CYP3A4 (0.72) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2725614 | 0.83 | CYP3A4 (0.77) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL2726281 | 0.83 | CYP3A4 (0.83) | CYP3A4CYP2C9BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | CYP3A4 163/4885CYP2C9 284/4885BRD4 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.